ANGLE plc (DWV) AI Stock Analysis
ANGLE plc
(Frankfurt:DWV)
No summary available
ANGLE plc (DWV) vs. iShares MSCI Germany ETF (EWG)
- Market Cap
- EUR 6.82M
- Dividend Yield
- ―
- Average Volume (3M)
- 50.00K
- Price to Earnings (P/E)
- -0.5
- Beta (1Y)
- -6.98
- Revenue Growth
- -57.57%
- EPS Growth
- 43.13%
- Country
- Germany
- Employees
- 114
- Sector
- Healthcare
- Sector Strength
- 51
- Industry
- Medical - Diagnostics & Research
ANGLE plc Business Overview & Revenue Model
Company Description
CelLBxHealth plc is a medical diagnostics firm specializing in the creation of cancer detection solutions, with operations spanning the United Kingdom, broader Europe, North America, and other global markets. A flagship offering is the Parsortix PC1...
ANGLE plc Earnings Call Summary
ANGLE's earnings call presented a balanced outlook with significant achievements in pharma collaborations and technology development, but also faced challenges from adverse market conditions affecting revenue and the need for additional funding.
Q2-2025 Updates
Positive Updates
Negative Updates
Company Guidance
During the ANGLE 2025 Interim Results Call, CEO Andrew Newland provided comprehensive guidance on the company's financial and operational progress for the first half of the fiscal year. Despite facing adverse market conditions that pressured revenue, with pharma revenue down and product revenue flat compared to the prior year, ANGLE has made significant strides in commercialization and development. Key achievements include the completion of three major pharma projects with Eisai and AstraZeneca, the development of the DNA dual analysis using Illumina's NGS assay, and the commencement of a collaboration with Myriad Genetics for large-scale commercialization of the Parsortix system. The company has maintained tight cost control, reducing operating expenditure by 12%, and holds a cash position of GBP 6.6 million, with a runway extending into Q1 2026. Despite the challenging environment, ANGLE anticipates further developments with multiple large pharma and med tech companies and is actively pursuing additional funding sources to ensure continued growth and innovation in its cancer diagnostic solutions.
ANGLE plc Peers Comparison
Overall Rating
GB:DXRX59Neutral
GB:GDR49Neutral
GB:ABDX46Neutral
GB:PRM40Underperform
GB:VRCI32Underperform
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| GB:DXRX | 59Neutral | GBP 171.90M | -637.50 | -0.68% | ― | 20.14% | 82.22% |
| Sector * | 51Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
| GB:GDR | 49Neutral | GBP 15.65M | -0.89 | -1044.57% | ― | 65.60% | 74.84% |
| GB:ABDX | 46Neutral | GBP 22.75M | -16.36 | -34.31% | ― | 30.42% | 43.16% |
| GB:PRM | 40Underperform | GBP 5.09M | -1.99 | 23.85% | ― | -16.72% | 36.28% |
| GB:VRCI | 32Underperform | GBP 14.32M | -0.54 | -127.57% | ― | 77.87% | 84.36% |
* Healthcare Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| DE:DWV | ANGLE plc | 0.01 | -0.01 | -54.55% | |
| GB:GDR | Genedrive plc | 0.97 | 0.12 | 13.50% | |
| GB:PRM | Proteome Sciences | 1.46 | -0.09 | -6.13% | |
| GB:DXRX | Diaceutics Plc | 204.00 | 40.00 | 24.39% | |
| GB:VRCI | Verici Dx Plc | 0.20 | -0.49 | -70.71% | |
| GB:ABDX | Abingdon Health PLC | 9.00 | 1.75 | 24.14% |
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.